Calithera Biosciences (CALA)

Executive Summary

Calithera Biosciences was a clinical-stage biotechnology company focused on developing novel small-molecule drugs targeting tumor metabolism and immuno-oncology. Its lead programs centered on arginase and glutaminase inhibition, aiming to disrupt metabolic processes critical for cancer cell growth and overcome immunosuppression in the tumor microenvironment. The company advanced several candidates into clinical trials for various cancer indications, including renal cell carcinoma, lymphoma, and solid tumors. Notable pipeline assets included telaglenastat (CB-839), a glutaminase inhibitor, and TAK-659, a SYK inhibitor. However, following a strategic review in February 2023, Calithera announced the discontinuation of all clinical development programs and subsequently wound down operations and dissolved. The company is no longer operational, and its stock was delisted. There are no ongoing or planned activities, clinical trials, or future prospects.